NCT00176579

Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer

Assessing Bone Mineral Density as a Risk Factor for Early Clinically Significant Prostate Cancer

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 27 (actual)
• Sponsor: University of Medicine and Dentistry of New Jersey · Academic / Other
• Sex: Male
• Age: 50 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Measuring bone mineral density may help doctors predict whether prostate cancer will come back. It may also help the study of prostate cancer in the future. PURPOSE: This clinical trial is studying whether bone mineral density affects cancer recurrence in patients with early stage prostate cancer.

Detailed description

OBJECTIVES: * Determine bone mineral density (BMD) in patients with clinically significant early stage prostate cancer. * Determine whether patients who have a higher level of BMD and have had a radical prostatectomy for cure are less likely to have an early relapse (i.e., less than 3 years) than those patients with a low level of BMD. OUTLINE: This is a case-controlled study followed by a prospective, longitudinal, cohort study. Patients undergo bone mineral density (BMD) measurements by dual-energy x-ray absorptiometry with a densitometer. Posteroanterior measurements of the total hip are also recorded. Patients also undergo blood collection to examine markers that provide evidence of systemic disease. Patients are followed every 6 months for 3 years. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Conditions

• Osteoporosis
• Prostate Cancer

Interventions

Type	Name	Description
PROCEDURE	dual x-ray absorptiometry	Dual x-ray absortiometry by densitometer will be performed to measure bone mineral density

Timeline

• Start date: 2003-06-01
• Primary completion: 2008-07-01
• Completion: 2008-07-01
• First posted: 2005-09-15
• Last updated: 2011-08-12

Locations

1 site across 1 country: United States